Legend Biotech (LEGN) Tops Q3 EPS by 14c

Legend Biotech (NASDAQ: LEGN) reported Q3 EPS of ($0.17), $0.14 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $96.01 million versus the consensus estimate of $97.42 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• BMO Capital Reiterates Outperform Rating on HF Sinclair (DINO)
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M